description

curl -X POST "https://api.tickerbot.io/v2/scan" \
  -H "Content-Type: application/json" \
  -H "Authorization: Bearer YOUR_KEY" \
  -d '{ "q": "description IS NOT NULL", "order": "description", "columns": "description" }'

{
 "as_of": "2026-09-18T14:38:17.020Z",
 "query": {
  "q": "description IS NOT NULL",
  "limit": 2,
  "order": "description",
  "dir": "desc",
  "fields": [
   "description"
  ],
  "full": false,
  "universe": null,
  "asset_class": null
 },
 "count": 2,
 "results": [
  {
   "ticker": "VTVT",
   "name": "vTv Therapeutics Inc. Class A Common Stock",
   "asset_class": "stocks",
   "asset_type": "CS",
   "price": 31.245,
   "change_1d_pct": -0.4936305732484,
   "gap_pct": -0.7962,
   "relative_volume": 0.6196,
   "market_cap": 120436646,
   "description": "vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases."
  },
  {
   "ticker": "QURE",
   "name": "uniQure N.V.",
   "asset_class": "stocks",
   "asset_type": "CS",
   "price": 44.09,
   "change_1d_pct": null,
   "gap_pct": 0.7031,
   "relative_volume": 0.1289,
   "market_cap": 2947378845,
   "description": "uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs."
  }
 ]
}